The regulation of the L‐type Ca2+ current (ICa) by intracellular cGMP was investigated in human atrial myocytes using the whole‐cell patch‐clamp technique.
Intracellular application of 0.5 μm cGMP produced a strong stimulation of basal ICa (+64 ± 5%, n= 60), whereas a 10‐fold higher cGMP concentration induced a 2‐fold smaller increase (+36 ± 8%, n= 35).
The biphasic response of ICa to cGMP was not mimicked by the cGMP‐dependent protein kinase (PKG) activator 8‐bromoguanosine 3′,5′ cyclic monophosphate (8‐bromo‐cGMP, 0.5 or 5 μm), and was not affected by the PKG inhibitor KT 5823 (100 nm).
In contrast, cGMP stimulation of ICa was abolished by intracellular perfusion with PKI (10 μm), a selective inhibitor of the cAMP‐dependent protein kinase (PKA).
Selective inhibition of the cGMP‐inhibited phosphodiesterase (PDE3) by extracellular cilostamide (100 nm) strongly enhanced basal ICa in control conditions (+78 ± 13%, n= 7) but had only a marginal effect in the presence of intracellular cGMP (+22 ± 7% in addition to 0.5 μm cGMP, n= 11; +20 ± 22% in addition to 5 μm cGMP, n= 7).
Application of erythro‐9‐[2‐hydroxy‐3‐nonyl]adenine (EHNA, 30 μm), a selective inhibitor of the cGMP‐stimulated phosphodiesterase (PDE2), fully reversed the secondary inhibitory effect of 5 μm cGMP on ICa (+99 ± 16% stimulation, n= 7).
Altogether, these data indicate that intracellular cGMP regulates basal ICa in human atrial myocytes in a similar manner to NO donors. The effect of cGMP involves modulation of the cAMP level and PKA activity via opposite actions of the nucleotide on PDE2 and PDE3.